Skip to content

Evaluating Sublingual immunotherapy in allergic Rhinoconjunctivitis

Evaluation of the Efficacy and Safety of Sublingual Immunotherapy ( Traditional Coca’s extract) in the treatment of Allergic Rhinoconjunctivitis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
PACTR
Registry ID
PACTR201901529431463
Enrollment
120
Registered
2019-01-15
Start date
2017-02-05
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ear, Nose and Throat Eye Diseases

Interventions

skin prick testing Sublingual immunotherapy and traditional pharmacological therapy as required
Traditional pharmacological therapy for allergy

Sponsors

Faculty of Medicine Zagazig University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adolescent or adult Patient with a history of moderate to severe chronic allergic rhinoconjunctivitis without any co-morbidities.

Exclusion criteria

Exclusion criteria: The study excluded any patient with active, acute, or chronic obstructive pulmonary disease, except for asthma and allergic rhinitis; forced expiratory volume in 1 s = 70% of predicted value; Patients who have disorders concerning drug absorption, distribution, metabolism, and excretion. Inability to perform Skin prick test in patients included in group 2. Illiterate patients who cannot read the self-administered quality of life questioner were also excluded. Refusal of consent.

Design outcomes

Primary

MeasureTime frame
Improvement of patients Quality of life

Secondary

MeasureTime frame
Improvement in patient Medication score

Countries

Egypt

Contacts

Public ContactAtef El Bahrawi

Professor of Otolaryngeology Faculty of Medicine Zagazig University

atefelbahrawi@gmail.com+201222430107

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026